"Our acquisition of ORCApharm, a well established player in the German oncology market, provides us with a strategic platform for entering the highly lucrative oncology business in Germany and strongly supports our corporate strategy of focusing on markets with greater barriers-to-entry and thus greater value," commented Å½eljko Čović, President of PLIVA's Management Board and COO. "The acquisition of ORCApharm and its current product portfolio further supports our commitment to the European oncology market and strengthens the foothold we have already established through our Czech subsidiary PLIVA Lachema, which focuses on the development, production and distribution of vertically integrated injectable cytostatic products. Furthermore, we are confident that we will deliver additional product synergies by expanding ORCA's portfolio to include select PLIVA and Barr products that complement oncology treatments, such as our pain and CNS franchises."
About PLIVA d.d.
PLIVA d.d. is the European generic pharmaceutical subsidiary of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operates in more than 30 countries. The Barr Group of companies is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.
Established in 1921 and with headquarters in Zagreb, Croatia, PLIVA is the leading Central and Eastern European (CEE) pharmaceutical company and has a portfolio of 550+ products that compete in the key markets of Croatia, Czech Republic, Germany, Poland and Russia. PLIVA's product portfolio includes solid dose forms, injectables, creams/ointments, Over-The-Counter (OTC) products, cytostatics, and active pharmaceutical ingredients (APIs). PLIVA is also an emerging participant in the generic biopharmaceutical arena. For more information visit http://www.pliva.com